The estimated Net Worth of Shaun D Mc Means is at least $488 mil dollars as of 1 December 2017. Mr Means owns over 945 units of HTG Molecular Diagnostics Inc stock worth over $20,305 and over the last 10 years he sold HTGM stock worth over $60,318. In addition, he makes $407,071 as Sr. VP, CFO y Sec. & Treasurer at HTG Molecular Diagnostics Inc.
Sign up
Mr McMeans HTGM stock SEC Form 4 insiders trading
Mr has made over 10 trades of the HTG Molecular Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 945 units of HTGM stock worth $1,994 on 1 December 2017.
The largest trade he's ever made was selling 5,651 units of HTG Molecular Diagnostics Inc stock on 10 March 2016 worth over $13,449. On average, Mr trades about 432 units every 15 days since 2015. As of 1 December 2017 he still owns at least 42,303 units of HTG Molecular Diagnostics Inc stock.
You can see the complete history of Mr Means stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Shaun D. McMeans biography
Shaun D. McMeans is the Sr. VP, CFO, Sec. & Treasurer at HTG Molecular Diagnostics Inc.
What is the salary of Mr McMeans?
As the Sr. VP, CFO y Sec. & Treasurer of HTG Molecular Diagnostics Inc, the total compensation of Mr McMeans at HTG Molecular Diagnostics Inc is $407,071. There are 2 executives at HTG Molecular Diagnostics Inc getting paid more, with John Lubniewski having the highest compensation of $1,157,740.
How old is Mr McMeans?
Mr McMeans is 59, he's been the Sr. VP, CFO y Sec. & Treasurer of HTG Molecular Diagnostics Inc since . There are 8 older and 8 younger executives at HTG Molecular Diagnostics Inc. The oldest executive at HTG Molecular Diagnostics Inc is Harry George, 71, who is the Independent Director.
What's Mr McMeans's mailing address?
Shaun's mailing address filed with the SEC is C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON, AZ, 85706.
Insiders trading at HTG Molecular Diagnostics Inc
Over the last 10 years, insiders at HTG Molecular Diagnostics Inc have traded over $5,630,772 worth of HTG Molecular Diagnostics Inc stock and bought 1,019,150 units worth $14,128,765 . The most active insiders traders include Plc Gsk, Holdings A/S Novo y Laurence W Lytton. On average, HTG Molecular Diagnostics Inc executives and independent directors trade stock every 64 days with the average trade being worth of $28,039. The most recent stock trade was executed by Stephen Barat on 8 June 2023, trading 888 units of HTGM stock currently worth $710.
What does HTG Molecular Diagnostics Inc do?
about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.
What does HTG Molecular Diagnostics Inc's logo look like?
Complete history of Mr Means stock trades at HTG Molecular Diagnostics Inc
HTG Molecular Diagnostics Inc executives and stock owners
HTG Molecular Diagnostics Inc executives and other stock owners filed with the SEC include:
-
John Lubniewski,
President, Chief Executive Officer, Director -
John L. Lubniewski,
Pres, CEO & Director -
Shaun D. McMeans,
Sr. VP, CFO, Sec. & Treasurer -
Shaun McMeans,
Chief Financial Officer, Senior Vice President, Treasurer, Secretary -
Byron T. Lawson,
Sr. VP & Chief Commercial Officer -
Timothy Johnson,
Executive Chairman of the Board -
Byron Lawson,
Senior Vice President and Chief Commercial Financial Officer -
Lee McCracken,
Independent Director -
James LaFrance,
Independent Director -
Donnie Hardison,
Independent Director -
Michelle Griffin,
Independent Director -
Harry George,
Independent Director -
Ann Hanham,
Lead Independent Director -
Laura Beggrow,
Pres of Diagnostics -
Dr. Stephen A. Barat Ph.D.,
Sr. VP of Therapeutics -
Dr. Marian Navratil Ph.D.,
Sr. VP of R&D -
Dr. Patrick C. Roche,
Sr. VP of R&D -
Dr. Debra A. Gordon,
Sr. VP & Chief Legal Counsel -
Laura Lee Godlewski,
Sr. VP of Fin. & Admin. -
Dr. Maureen T. Cronin Ph.D.,
Sr. VP & Chief Scientific Officer -
Christopher P Kiritsy,
Director -
Stephen Barat,
Senior VP of Therapeutics -
Debra A Gordon,
V.P. and Chief Legal Counsel -
Lewis Shuster,
Director -
Plc Gsk,
10% owner -
Don M Hardison,
Director -
Holdings A/S Novo,
10% owner -
Nv Qiagen,
10% owner -
Patrick C. Roche,
SVP Research & Development -
Spaght Ventures Ii Lpfsv Ii...,
-
Donald W Grimm,
Director -
Capital Ventures Llc Senour...,
-
Tim B Johnson,
Executive Chairman -
Laurence W Lytton,
10% owner -
Thomas W. Dubensky,
Director -
Laura Lee Godlewski,
SVP Finance & Administration